Abstract: A pressure regulating device includes an on-board storage tank, a mixing chamber, first and second lines, a recirculation line, a pressure sensor and a controller. The storage tank stores and supplies cryogenic fuel to a combustion chamber and includes a booster pump. The first line supplies cryogenic fuel in the liquid state and includes a pressurizing pump and a first regulation valve. The second line supplies cryogenic fuel in the gaseous state and includes a compressor and a first control valve. The recirculation line includes a second regulation valve and with a first heat exchanger. The pressure sensor detects the pressure inside the storage tank. The controller receives the pressure and controls the first and second regulation valves, the first control valve, the pressurizing pump, the booster pump and the compressor, as a function of a value of a setpoint pressure inside the storage tank.

Abstract: A compound of formula (I) in which R? represents a group —(CRaRb)n—X—(CRcRd)m—[Y—(CReRf)o]t—NR9R10 and X and Y independently represent a group —NR11-, a group —O— or a divalent 5-membered or 6-membered heterocyclic group comprising at least one nitrogen atom, and also the stereoisomers, mixtures of stereoisomers, and/or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical or veterinary compositions containing the compound of formula (I) and also to the use thereof as medicament, more particularly in the treatment of bacterial, fungal, viral or parasitic infections. Also further disclosed are pharmaceutical or veterinary compositions including the compound of formula (I) in combination with an antibiotic other than such a compound of formula (I).

Abstract: The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.

Abstract: A compound of formula (I) in which R? represents a group —(CRaRb)n—X—(CRcRd)m—[Y—(CReRf)o]t—NR9R10 and X and Y independently represent a group —NR11-, a group —O— or a divalent 5-membered or 6-membered heterocyclic group comprising at least one nitrogen atom, and also the stereoisomers, mixtures of stereoisomers, and/or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical or veterinary compositions containing the compound of formula (I) and also to the use thereof as medicament, more particularly in the treatment of bacterial, fungal, viral or parasitic infections. Also further disclosed are pharmaceutical or veterinary compositions including the compound of formula (I) in combination with an antibiotic other than such a compound of formula (I).

Abstract: A compound of formula (I) in which R? represents a group —(CRaRb)n—X—(CRcRd)m—[Y—(CReRf)o]t—NR9R10 and X and Y independently represent a group —NR11-, a group —O— or a divalent 5-membered or 6-membered heterocyclic group comprising at least one nitrogen atom, and also the stereoisomers, mixtures of stereoisomers, and/or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical or veterinary compositions containing same, which may be used as a medicament, more particularly, in the treatment of bacterial, fungal, viral or parasitic infections. In certain aspects, these pharmaceutical or veterinary compositions include the compound of formula (I) in combination with an antibiotic other than such a compound of formula (I).

Abstract: Suggested is the use of a mixture, comprising (a) fatty acid alkyl esters according to general formula (I) R1COO—R2 (I) in which R1CO represents an unsaturated acyl radical having 16 to 22 carbon atoms and 1, 2 or 3 double bonds, and R2 represents a C1-C4 alkyl radical; (b) at least two non-ionic sugar or polyol surfactants, and optionally (c) polyols as an additive for agricultural compositions.

Abstract: The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.

Abstract: The present invention relates to a veterinary pharmaceutical composition containing torasemide to be used for treating cardiac failure. The torasemide is administered in a daily dose of 0.02 mg/kg to 0.1 mg/kg during long-term treatment.

Abstract: The present invention relates to the use, as active ingredient, of a 1-N-(halo-3-pyridylmethyl)-N-methylamino-1-alkylamino-2-nitroethylene derivative for preparing a veterinary pharmaceutical composition for topical application in the treatment of external parasites, in particular fleas, in domestic animals, in particular in dogs and cats, intended to be applied at least every 2 weeks.

Abstract: The present invention relates to the use, as active ingredient, of a 1-N-(halo-3-pyridylmethyl)-N-methylamino-1-alkylamino-2-nitroethylene derivative for preparing a veterinary pharmaceutical composition for topical use in the treatment of external parasites, in particular fleas, in domestic animals, in particular in dogs and cats, intended to be applied at least every 2 weeks.

Abstract: The present invention relates to the use, as active ingredient, of a 1-N-(halo-3-pyridylmethyl)-N-methylamino-1-alkylamino-2-nitroethylene derivative for preparing a veterinary pharmaceutical composition for topical use in the treatment of external parasites, in particular fleas, in domestic animals, in particular in dogs and cats, intended to be applied at least every 2 weeks.

Abstract: An unsaturated fatty acid precursor of a natural 1,3-diol derivative, which precursor is the same as that which is naturally present in a cider apple, is enzymatically converted to the natural 1,3-diol derivative.

Abstract: A process for increasing the yield of natural vanilla flavor. Green vanilla pods are hydrated. The resulting hydrated pods are ground, forming a liquid phase and a solid phase. The resulting ground hydrated product of green vanilla pods is treated with an enzymatic system including at least one enzyme. The enzyme system possesses from about 10 to about 1000 units of beta-glucose activity per gram of green vanilla pods. The ground hydrated green vanilla pods and the enzymatic system are incubated at a temperature of from about 10.degree. C. to about 40.degree. C. for a period of between about 2 hours and about 30 hours sufficient to allow the release of the vanilla flavor. The liquid phase containing the vanilla flavor is separated from the solid phase.